Clinical characteristics of male patients with breast cancer in the Latino population.
BRCA2 genes
Breast cancer
Male breast neoplasms
Triple negative breast neoplasms
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
29
07
2024
accepted:
10
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
aheadofprint
Résumé
Breast cancer is the most prevalent cancer type in Mexico, with male breast cancer accounting for only 1% of all breast cancer cases. A limited number of studies have described the clinical-pathological profiles of males with breast cancer in low- and middle-income countries. This study presents an analysis of patients with breast cancer seen at three different institutions in México. A retrospective review of the medical records was performed to analyze the clinical and pathological characteristics of 49 men diagnosed with breast cancer and their overall survival. The mean age at diagnosis was 64.65 years. A significant proportion of patients presented at diagnosis with stage IV disease (n = 11, 22.45%), had triple-negative subtype (n = 6, 12.24%), and nuclear grade III (n = 20, 40.8%). Primary endocrine resistance was observed in 10 patients (31.25%). Genetic analysis was performed on 24 patients (48.9%), revealing a germline BRCA pathogenic variant in 8.33%. Our findings described the clinical and pathological profile of breast cancer in a male cohort in Mexico, with a significantly high proportion of advanced disease, triple-negative subtype, nuclear grade III, and endocrine resistance. Further comprehensive studies, including research into somatic mutations, are needed.
Identifiants
pubmed: 39470849
doi: 10.1007/s10549-024-07525-1
pii: 10.1007/s10549-024-07525-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ferlay J et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953. https://doi.org/10.1002/ijc.31937
doi: 10.1002/ijc.31937
pubmed: 30350310
Unger-Saldaña K et al (2023) Breast cancer survival in Mexico between 2007 and 2016 in women without social security: a retrospective cohort study. Lancet Reg Health - Am. https://doi.org/10.1016/j.lana.2023.100541
doi: 10.1016/j.lana.2023.100541
pubmed: 37408951
pmcid: 10319338
American Cancer Society (2023) Cancer facts & figures 2023. American Cancer Society
Unger-Saldaña K (2014) Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol 5(3):465–477. https://doi.org/10.5306/wjco.v5.i3.465
doi: 10.5306/wjco.v5.i3.465
pubmed: 25114860
pmcid: 4127616
Dafni U, Tsourti Z, Alatsathianos I (2019) Breast cancer statistics in the European union: incidence and survival across European countries. Breast Care 14(6):344–353. https://doi.org/10.1159/000503219
doi: 10.1159/000503219
pubmed: 31933579
pmcid: 6940474
Giordano SH (2018) Breast cancer in men. N Engl J Med 378(24):2311–2320. https://doi.org/10.1056/NEJMra1707939
doi: 10.1056/NEJMra1707939
pubmed: 29897847
Fox S, Speirs V, Shaaban AM (2022) Male breast cancer: an update. Virchows Arch 480(1):85–93. https://doi.org/10.1007/s00428-021-03190-7
doi: 10.1007/s00428-021-03190-7
pubmed: 34458944
Chávez-Hernández NH, Salamanca-García M (2014) Epidemiología del cáncer de mama en hombres atendidos en el Centro Médico Nacional 20 de Noviembre. Rev Esp Méd Quir 19:267–271
AlFehaid M (2023) Male breast cancer (MBC)—a review. Polish J Surg 95(6):24–30. https://doi.org/10.5604/01.3001.0016.3174
doi: 10.5604/01.3001.0016.3174
Amin MB et al (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin 67(2):93–99. https://doi.org/10.3322/caac.21388
doi: 10.3322/caac.21388
pubmed: 28094848
Allison KH et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38:1346–1366. https://doi.org/10.1200/JCO.19
doi: 10.1200/JCO.19
pubmed: 31928404
“her2_guidelines_wolff_2018”.
Cardoso F et al (2017) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 28(1):16–33. https://doi.org/10.1093/annonc/mdw544
doi: 10.1093/annonc/mdw544
pubmed: 28177437
Salazar-Mejía CE et al (2019) Breast cancer in men: a 10-year experience of an oncology reference center in Northeast Mexico. J Cancerol 6:21–27
Lissidini G et al (2024) Male breast cancer: a multicenter study to provide a guide for proper management. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-024-07380-0
doi: 10.1007/s10549-024-07380-0
pubmed: 38896332
Cardoso F et al (2018) Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program. Ann Oncol 29(2):405–417. https://doi.org/10.1093/annonc/mdx651
doi: 10.1093/annonc/mdx651
pubmed: 29092024
Grajales-Alvarez R, Gutiérrez-Mata A, Pichardo-Piña C, Gutiérrez-De la Barrera M, Dip-Borunda K (2024) Survival outcomes of patients with breast cancer in a Mexican population. JCO Glob Oncol. https://doi.org/10.1200/GO.23.00233
doi: 10.1200/GO.23.00233
pubmed: 38330273
pmcid: 10861020
Zheng G, Leone JP (2022) Male breast cancer: an updated review of epidemiology, clinicopathology, and treatment. J Oncol. https://doi.org/10.1155/2022/1734049
doi: 10.1155/2022/1734049
pubmed: 37251557
pmcid: 9822749
Li A, Schleicher SM, Andre F, Mitri ZI (2024) Genomic alteration in metastatic breast cancer and its treatment. Am Soc Clin Oncol Educ Book. https://doi.org/10.1200/EDBK_
doi: 10.1200/EDBK_
Campos FAB et al (2021) Genetic landscape of male breast cancer. Cancers. https://doi.org/10.3390/cancers13143535
doi: 10.3390/cancers13143535
pubmed: 34572835
pmcid: 8472653
Ibrahim M, Yadav S, Ogunleye F, Zakalik D (2018) Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. https://doi.org/10.1186/s12885-018-4098-y
doi: 10.1186/s12885-018-4098-y
pubmed: 30428857
pmcid: 6234700
Weitzel JN et al (2013) Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the clinical cancer genetics community research network. J Clin Oncol 31(2):210–216. https://doi.org/10.1200/JCO.2011.41.0027
doi: 10.1200/JCO.2011.41.0027
pubmed: 23233716
Gucalp A et al (2019) Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treatment 173(1):37–48. https://doi.org/10.1007/s10549-018-4921-9
doi: 10.1007/s10549-018-4921-9
Lei JT, Anurag M, Haricharan S, Gou X, Ellis MJ (2019) Endocrine therapy resistance: new insights. Breast 48:S26–S30. https://doi.org/10.1016/S0960-9776(19)31118-X
doi: 10.1016/S0960-9776(19)31118-X
pubmed: 31839155
Hartkopf AD, Grischke EM, Brucker SY (2020) Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care 15(4):347–354. https://doi.org/10.1159/000508675
doi: 10.1159/000508675
pubmed: 32982644
pmcid: 7490658
Moelans CB et al (2019) The molecular genetic make-up of male breast cancer. Endocr Relat Cancer 26(10):779–794. https://doi.org/10.1530/ERC-19-0278
doi: 10.1530/ERC-19-0278
pubmed: 31340200
pmcid: 6938562
Piscuoglio S et al (2016) The genomic landscape of male breast cancers. Clin Cancer Res 22(16):4045–4056. https://doi.org/10.1158/1078-0432.CCR-15-2840
doi: 10.1158/1078-0432.CCR-15-2840
pubmed: 26960396
pmcid: 4987160
Xie J, Ying YY, Xu B, Li Y, Zhang X, Li C (2019) Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database. Ther Adv Med Oncol. https://doi.org/10.1177/1758835919889003
doi: 10.1177/1758835919889003
pubmed: 31798694
pmcid: 6859799
Leone J et al (2024) Mortality risks over 20 years in men with stage I to III hormone receptor-positive breast cancer. JAMA Oncol 10(4):508–515. https://doi.org/10.1001/jamaoncol.2023.7194
doi: 10.1001/jamaoncol.2023.7194
pubmed: 38421673